-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For COVID-19 , there is currently no effective drug treatment
.
Host-directed therapies for potentially abnormal immune responses that cause lung tissue damage, death, or long-term dysfunction in survivors require further clinical evaluation
COVID-19 immune stem cells
The study recruited 18 hospitalized COVID-19 patients (n = 9 in each group)
.
The treatment group received three cycles of intravenous infusion of UC-MSCs (3×107 cells per infusion) on days 0, 3, and 6
No serious adverse events related to the infusion of UC-MSCs were observed during the study
.
Two patients who received UC-MSCs developed transient facial flushing and fever, and one patient developed transient hypoxia 12 hours after UC-MSCs infusion
In summary, the data of the study shows that intravenous infusion of UC-MSCs in patients with moderate to severe COVID-19 is safe and well tolerated
.
A phase 2/3 randomized, controlled, double-blind trial with long-term follow-up is needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve the long-term treatment effect of patients with severe COVID-19
Original source:
Fanping Meng, Ruonan Xu, et al.
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial in this message